// App-Quantinova.ai

Mo1097 : Adalimumab Improves Treatment Satisfaction With Medication and Work Productivity Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From INSPIRADA

Researchers

Presenter

  • Brian G. Feagan

Principal Investigators

  • Laurent Peyrin-Biroulet

  • Song Wang

  • Roopal B. Thakkar

  • Jingdong Chao

  • Remo Panaccione

  • Silvio Danese

  • Andreas Lazar

  • Anne M. Robinson

  • Joel H. Petersson

  • Mareiki Bereswill

  • Martha Skup

  • Naijun Chen

Medical Centers

  • Istituto Clinico Humanitas, Milan, Italy

  • University Hospital of Lille, Lille, France

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • University of Calgary, Calgary, AB, Canada

  • Robarts Reserach Institute, London, ON, Canada

Locations

  • France

  • Canada

  • United Kingdom

  • Italy

Companies

  • AbbVie Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Inflammatory bowel disease

  • Ulcerative colitis

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Adalimumab

Outcome

  • Unknown

Study Design

  • open label

  • randomized

  • single arm

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved